Table 2 Effect of canagliflozin on HbA1c levels

Total

 N

70

76

 Mean (SD) baseline (%)

8.85 (0.84)

8.89 (0.81)

 LS mean (SE) change (%)^a

0.13 (0.08)

−0.97 (0.08)

 Difference (95 % CI) vs placebo (%)

–

−1.10 (−1.33, −0.87)

 p value

<0.001

 N

66

73

 LS mean (SE) change (%)^b

0.15 (0.08)

−0.98 (0.08)

 Difference (95 % CI) vs placebo (%)

–

−1.13 (−1.36, −0.89)

 p value

–

<0.001

Each insulin regimen

 Premixed

  N

26

28

  Mean (SD) baseline (%)

8.70 (0.82)

8.73 (0.73)

  LS mean (SE) change (%)^a

−0.01 (0.13)

−0.89 (0.12)

  Difference (95 % CI) vs placebo (%)

–

−0.88 (−1.24, −0.52)

  p value

–

<0.001

 Long-acting

  N

24

24

  Mean (SD) baseline (%)

8.89 (0.85)

9.02 (0.87)

  LS mean (SE) change (%)^a

0.26 (0.12)

−1.18 (0.12)

  Difference (95 % CI) vs placebo (%)

–

−1.44 (−1.79, −1.09)

  p value

–

<0.001

 Premixed + rapid- or short-acting

  N

1

0

  Mean (SD) baseline (%)

7.50 (−)

–

  LS mean (SE) change (%)^a

0.10 (0.00)

–

 Long-acting + rapid- or short-acting

  N

19

24

  Mean (SD) baseline (%)

9.09 (0.80)

8.96 (0.83)

  LS mean (SE) change (%)^a

0.17 (0.19)

−0.83 (0.17)

  Difference (95 % CI) vs placebo (%)

–

−1.00 (−1.51, −0.49)

  p value

–

<0.001